title: Long-term safety, efficacy, and tolerability of imidafenacin in the treatment of overactive bladder: a review of the Japanese literature.
abstract: Imidafenacin is an antimuscarinic agent with high affinity for the M(3) and M(1) muscarinic receptor subtypes and low affinity for the M(2) subtype, and is used to treat overactive bladder. Several animal studies have demonstrated that imidafenacin has organ selectivity for the bladder over the salivary glands, colon, heart, and brain. In Phase I studies in humans, the approximately 2.9-hour elimination half-life of imidafenacin was shorter than that of other antimuscarinics such as tolterodine and solifenacin. Imidafenacin was approved for clinical use in overactive bladder in Japan in 2007 after a randomized, double-blind, placebo-controlled Phase II study and a propiverine-controlled Phase III study conducted in Japanese patients demonstrated that imidafenacin 0.1 mg twice daily was clinically effective for treating overactive bladder and was not inferior to propiverine for reduction of episodes of incontinence, with a better safety profile than propiverine. Several short-term clinical studies have demonstrated that imidafenacin also improves sleep disorders, nocturia, and nocturia-related quality of life. In addition, it is speculated that addon therapy with imidafenacin is beneficial for men with benign prostatic hyperplasia whose overactive bladder symptoms are not controlled by alpha-1 adrenoceptor antagonists. No cognitive impairment or influence of imidafenacin on the QTc interval has been observed. Although there have been very few relevant long-term clinical studies, the available information suggests the long-term efficacy, safety, and tolerability of imidafenacin, with less frequent severe adverse events, such as dry mouth and constipation. In addition, imidafenacin can be used safely for a long time even for cognitively vulnerable elderly patients with symptoms of overactive bladder. Thus, it is highly likely that imidafenacin is safe, efficacious, and tolerable to control symptoms of overactive bladder even over the long term. However, it remains unknown if the practical effectiveness of imidafenacin is applicable to ethnic groups other than Japanese.
authors: Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan.
authors: Naoya
authors: N
authors: Masumori
keywords: antimuscarinics; imidafenacin; long-term efficacy; overactive bladder
references: Int J Urol. 2009 Feb;16(2):126-42
references: 19228224
references: BJU Int. 2005 Dec;96(9):1314-8
references: 16287452
references: Br J Clin Pharmacol. 2008 Feb;65(2):197-202
references: 18251758
references: J Urol. 2012 Dec;188(6 Suppl):2455-63
references: 23098785
references: Adv Urol. 2011;2011:854697
references: 22046182
references: Low Urin Tract Symptoms. 2012 Sep;4(3):130-5
references: 26676619
references: Int J Urol. 2009 May;16(5):499-506
references: 19389083
references: Hinyokika Kiyo. 2011 Jan;57(1):1-6
references: 21304252
references: Urology. 2004 Mar;63(3):481-6
references: 15028442
references: Urol Int. 2003;71(3):290-8
references: 14512651
references: Neurourol Urodyn. 2010;29(1):4-20
references: 19941278
references: Arzneimittelforschung. 2007;57(3):147-54
references: 17469649
references: J Pharmacol Exp Ther. 2011 Feb;336(2):365-71
references: 21047953
references: Drug Metab Pharmacokinet. 2013;28(3):203-12
references: 23089801
references: Drug Metab Pharmacokinet. 2008;23(6):456-63
references: 19122340
references: Neuroimage. 2011 Sep 1;58(1):1-9
references: 21712096
references: Eur Urol. 2003 Jan;43(1):1-5
references: 12507537
references: J Urol. 2013 Apr;189(4):1388-95
references: 23079373
references: Naunyn Schmiedebergs Arch Pharmacol. 2011 Sep;384(3):319-29
references: 21814879
references: BMJ. 2012 Apr 17;344:e2365
references: 22511208
references: Int J Urol. 2008 Sep;15(9):809-15
references: 18637156
references: Drug Metab Dispos. 2007 Sep;35(9):1624-33
references: 17567733
references: Biomed Res. 2009 Apr;30(2):107-12
references: 19420734
references: J Urol. 2011 Jun;185(6):2392-7
references: 21511278
references: Urol Int. 2012;89(2):215-21
references: 22832092
references: Life Sci. 2010 Jul 31;87(5-6):175-80
references: 20598326
references: Int Psychogeriatr. 1997;9 Suppl 1:65-9
references: 9447429
references: Acta Psychiatr Scand. 2009 Apr;119(4):252-65
references: 19236314
references: Int J Urol. 2011 Nov;18(11):741-56
references: 22050351
references: Int J Urol. 2008 Oct;15(11):986-91
references: 18761536
references: Neurourol Urodyn. 2002;21(2):167-78
references: 11857671
references: Urol Int. 2011;86(3):330-3
references: 21325789
references: Arzneimittelforschung. 2007;57(2):92-100
references: 17396619
references: Xenobiotica. 2007 Feb;37(2):139-54
references: 17484517